On August 12, 2024, Amgen filed a BPCIA complaint in the District Court for the District of New Jersey against Samsung Bioepis and Samsung Biologics related to Samsung Bioepis’s proposed biosimilar of Amgen’s PROLIA and XGEVA.  This is the third BPCIA litigation regarding denosumab, following Amgen’s litigations against Sandoz and Celltrion, also filed in the…